425: Waters and BD Biosciences & Diagnostic Solutions Announce Transformative $17.5 Billion Reverse Morris Trust Combination

Waters Corporation and Becton, Dickinson and Company announced a definitive agreement for Waters to acquire BD's Biosciences & Diagnostic Solutions business via a Reverse Morris Trust, creating a life science and diagnostic leader with pro-forma revenue of $6.5 billion and adjusted EBITDA of $2 billion for 2025.

Summary

• Waters will acquire BD's Biosciences & Diagnostic Solutions business via a Reverse Morris Trust, issuing 39.2% of its shares to BD shareholders and assuming $4 billion of debt.
• The transaction is valued at approximately $17.5 billion, creating a combined company expected to generate pro-forma revenue of about $6.5 billion and adjusted EBITDA of approximately $2 billion for 2025.
• The combined entity will retain the name Waters and ticker WAT, employ approximately 16,000 people, and maintain its headquarters in Milford, Massachusetts.
• The combination doubles Waters' total addressable market to approximately $40 billion, expanding into durable volume-driven end markets projected to grow 5-7% annually.
• Over 70% of the combined company's revenue will be annually recurring, with over half of combined instrument revenue linked to routine replacement cycles of 5-10 years.
• The deal is expected to be adjusted EPS accretive in year one, with projected midto high-single-digit revenue growth and mid-teens adjusted EPS growth through the end of the decade.
• Significant cost synergies of $200 million are expected by year three, and revenue synergies of $290 million by year five, contributing to an annualized EBITDA of approximately $345 million by year five.
• Adjusted operating margin is anticipated to expand by approximately 500 basis points by 2030, reaching 32%, with net leverage expected to reduce to below two times within 18 months.
• In fiscal year 2024, BD Biosciences generated $1.5 billion in revenue from a $7 billion market, and BD Diagnostic Solutions delivered $1.8 billion in revenue from a $15 billion market.
• Combined, BD's Biosciences & Diagnostic Solutions businesses generated approximately $3.4 billion in revenue in fiscal 2024, with over 80% recurring revenue and an approximately 26% adjusted EBITDA margin.
• Waters' total revenue in 2024 was around $3 billion, with EBITDA of $1.1 billion and an adjusted operating margin of 31%.

Sentiment

Score: 9

Explanation: The document presents a highly positive and transformative business combination with strong financial projections, significant synergy potential, and strategic alignment, indicating a very optimistic outlook.

Positives

• Creates an innovation leader with robust financial strength, serving high-volume regulated applications with industry-leading brands.
• Significantly expands Waters' total addressable market to approximately $40 billion (from $19 billion), with durable end markets growing 5-7% annually.
• Offers unparalleled strategic fit, allowing Waters to immediately apply its proven commercial tools and advance strategic ambitions in high-growth areas like BioSeparations, Bioanalytical Characterizations, and Multiplex Diagnostics.
• Enhances growth stability with over 70% of revenue being annually recurring and over half of instrument revenue linked to routine replacement (every 5-10 years).
• Supports an industry-leading financial outlook with midto high-single-digit revenue growth, mid-teens adjusted EPS growth, rapid EPS accretion (year one), and leading cash flow generation.
• Expected to deliver significant cost synergies of $200 million by year three and revenue synergies of $290 million by year five.
• Rapid path to industry flagship margin levels, with adjusted operating margin expected to expand by 500 basis points by 2030, reaching 32%.
• Balance sheet will remain healthy and flexible with rapid deleveraging (below two times within 18 months).
• BD Biosciences is the undisputed pioneer in flow cytometry, and BD Diagnostic Solutions is a pioneer in microbiology research and clinical diagnostics.
• BD's businesses are anchored by a vast installed base of products (flow cytometry, microbiology, molecular diagnostics) and have strong innovation pipelines, including new FACSDiscover instruments, BD MAX, BD COR, Onclarity HPV assay, and next-generation BACTEC system.
• Waters' proven execution playbook (instrument replacement, service plan attachment, e-commerce adoption, new product launch excellence) can be applied to BD's businesses, leveraging BD's 70,000 installed instruments (20,000 due for replacement in next two years) and 20% e-commerce penetration.
• Complementary customer bases and attractive cross-selling opportunities, such as for tandem quad mass spectrometers into pharma drug metabolism and pharmacokinetics.
• Waters' expertise in downstream high-volume applications enables capturing growth in biologics, GLP-1s, and generic off-patent therapeutics.
• Waters' Empower platform is used for approximately 80% of novel drugs submitted to FDA, EMA, and China NMPA, indicating a strong market position.
• The combination accelerates innovation in bioseparations by pairing Waters' chemistry expertise with BD's biology expertise and reagents.
• Enables Waters to bring flow cytometry downstream into large molecule QA/QC, leveraging Empower and BD's reagents, as flow cytometry is already used for cell therapy release testing.
• Advances Waters' ambition to bring LC-MS further into multiplex diagnostics by gaining BD's regulatory and market access capabilities, global commercial reach, reagents, and automated sample prep.
• The transaction multiple is attractive at 13.8 times with run rate synergies and 18.9 times on a pre-synergy basis.
• BD Biosciences business is described as 'spring-loaded to recover' as academic government spending returns, with new innovations like FACSDiscover A8 showing strong initial sales.
• Resolved supply issues for BACTEC business and mitigated import ban on flow cytometers into China, with localized manufacturing of FACSLyric in China.

Risks

• One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations or restrictions in connection with such approvals.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges or expenses resulting from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability.
• Evolving legal, regulatory and tax regimes.
• Changes in general economic and/or industry specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• The risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction, or other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
• The credit ratings of the combined company declines following the proposed transaction.
• The announcement or the consummation of the proposed transaction has a negative effect on the market price of the capital stock of Waters and BD or on Waters and BD's operating results.

Future Outlook

The combined company is projected to achieve midto high-single-digit annualized revenue growth and mid-teens annualized adjusted EPS growth through the end of the decade. It expects to expand its adjusted operating margin by approximately 500 basis points over five years, reaching 32% by 2030, with revenue reaching $9 billion and adjusted EBITDA $3.3 billion. The deal is expected to be adjusted EPS accretive in year one, and net leverage is targeted to be below two times within 18 months.

Management Comments

• "We are thrilled to announce today that Waters has agreed to issue 39.2% of its shares to BD shareholders and assume $4 billion of debt to acquire the BD Biosciences & Diagnostic Solutions business." Dr. Udit Batra, Waters President and CEO.
• "This is a rare and powerful opportunity to unite two industry leaders with complementary capabilities, a legacy of pioneering science and a shared, deep-rooted culture of innovation." Dr. Udit Batra, Waters President and CEO.
• "For 2025, the combined company is expected to generate pro-forma revenue of about $6.5 billion, with adjusted EBITDA of approximately $2 billion." Dr. Udit Batra, Waters President and CEO.
• "This combination positions us to deliver exceptional long-term benefits for customers and shareholders by uniting Waters leadership in downstream analytical workflows with BDs strength in cellular analysis and diagnostics." Dr. Udit Batra, Waters President and CEO.
• "Over 70% of revenue is annually recurring. In addition, over half of combined instrument revenue consists of routine replacement, which takes place after 5-10 years." Dr. Udit Batra, Waters President and CEO.
• "We expect significant cost and revenue synergies, a rapid path to industry flagship margin levels and strong growth at both the top and bottom line." Dr. Udit Batra, Waters President and CEO.
• "We expect approximately $200 million of annualized cost synergies by year three and 290 million in revenue synergies expected by year five, driving strong value creation." Dr. Udit Batra, Waters President and CEO.
• "The combined company offers an industry-leading financial outlook with projected midto high-single-digit annualized revenue growth and mid-teens annualized EPS growth through the end of the decade." Dr. Udit Batra, Waters President and CEO.
• "We believe this transaction represents both a tremendous outcome for the Biosciences & Diagnostic Solutions business and creates significant value for shareholders." Tom Polen, BD Chairman, CEO, and President.
• "Ultimately, we determined that an RMT with Waters is the ideal structure to immediately unlock value for BD shareholders and create a unique opportunity to participate in the upside of the combined company." Tom Polen, BD Chairman, CEO, and President.
• "BD Biosciences is the undisputed pioneer that invented the modern field of flow cytometry." Tom Polen, BD Chairman, CEO, and President.
• "In fiscal year 2024, Biosciences generated $1.5 billion in revenue, addressing a $7 billion market growing high-single-digits." Tom Polen, BD Chairman, CEO, and President.
• "In fiscal year 2024, Diagnostic Solutions delivered $1.8 billion in revenue, addressing a $15 billion market growing mid-single-digits-plus." Tom Polen, BD Chairman, CEO, and President.
• "In fiscal 2024, together these businesses generated approximately $3.4 billion in revenue, with over 80% recurring revenue and an approximately 26% adjusted EBITDA margin." Tom Polen, BD Chairman, CEO, and President.
• "At Waters, we too have built a highly repeatable business model centered around downstream regulated applications where high throughput, compliance, and reliability are critical." Dr. Udit Batra, Waters President and CEO.
• "Approximately 80% of novel drugs submitted to the FDA, EMA, and the China NMPA are done so using Empower." Dr. Udit Batra, Waters President and CEO.
• "Waters enters this transaction from a position of strength. In 2024, our total revenue was around $3 billion, with EBITDA of $1.1 billion and an industry-leading adjusted operating margin of 31%." Dr. Udit Batra, Waters President and CEO.
• "We expect approximately $200 million of annualized cost synergies by year three post-closing... We are also very confident that we can deliver approximately $290 million of annualized revenue synergies by year five post-closing." Amol Chaubal, Waters Senior Vice President and CFO.
• "By 2030, we expect to reach $9 billion in revenue and $3.3 billion in adjusted EBITDA, with an industry-leading 32% adjusted operating margin percentage." Amol Chaubal, Waters Senior Vice President and CFO.
• "We also expect to reduce net leverage to below two times within 18 months." Amol Chaubal, Waters Senior Vice President and CFO.
• "The name of the combined company will remain Waters and will be listed on the New York Stock Exchange under the ticker WAT." Dr. Udit Batra, Waters President and CEO.
• "The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, Waters shareholder approval, and satisfaction of other customary closing conditions." Dr. Udit Batra, Waters President and CEO.
• "This transaction is not just additive, it is transformational." Dr. Udit Batra, Waters President and CEO.
• "BD has 75,000 instruments installed, 20,000 are up for replacement in the next two years, 20,000." Dr. Udit Batra, Waters President and CEO.
• "BD Biosciences business is spring-loaded to recover. As that markets come back, its reset at a lower base, and the innovations that were launching are truly changing the category." Tom Polen, BD Chairman, CEO, and President.

Industry Context

The transaction creates a new leader in the life science tool industry by combining Waters' leadership in downstream analytical workflows (liquid chromatography, mass spectrometry) with BD's strength in cellular analysis and diagnostics (flow cytometry, microbiology, molecular diagnostics). This merger addresses the growing demand in regulated, high-volume applications driven by factors like pill count, infection rates, and disease detection, serving a global aging population. It positions the combined entity to capitalize on high-growth adjacencies such as BioSeparations, Bioanalytical Characterizations, and Multiplex Diagnostics, areas where both companies bring complementary expertise and technologies. The focus on recurring revenue and routine instrument replacement aligns with a trend towards more stable and predictable growth profiles in the life sciences tools sector, bridging capital expenditure cycles.

Comparison to Industry Standards

• The combined company's expected R&D spend at 10% of product sales is described as 'industry-leading'.
• The target of 32% adjusted operating margin by 2030 is stated to be 'industry flagship margin levels' and 'at the top of the sector'.
• Waters' standalone organic growth, adjusted EBITDA margin, and free cash flow as a percentage of revenue have been 'well above the peer group average'.
• BD Biosciences is described as the 'undisputed pioneer' in flow cytometry.
• BD Diagnostic Solutions is a 'pioneer' in microbiology research and clinical diagnostics.
• The new FACSDiscover instruments are 'setting a new standard in the industry'.
• Waters' Empower platform is used for approximately 80% of novel drugs submitted to FDA, EMA, and China NMPA, indicating a dominant position in regulated pharmaceutical workflows.
• E-commerce penetration for antibody portfolios is typically between 50% and 75%, indicating significant headroom for BD's 20% penetration to grow towards Waters' 40% and beyond.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder litigation in connection with the proposed transaction or other litigation, settlements or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability.

Stakeholder Impact

• Shareholders (Waters): Expected to benefit from significant long-term value creation, expanded market opportunities, enhanced growth stability, industry-leading financial outlook, and EPS accretion. Will own approximately 60.8% of the combined company.
• Shareholders (BD): Expected to immediately unlock value through the Reverse Morris Trust structure and participate in the upside of the combined company (owning 39.2%). Also enables BD to become a 'scale pure play med tech leader' with enhanced focus.
• Customers: Expected to benefit from broader capabilities, best-in-class technologies, accelerated innovation, and improved service offerings (e.g., 24-hour premier service).
• Employees: The combined company will have approximately 16,000 employees. Management expressed confidence in ensuring employees 'continue their legacy of delivering innovative, meaningful solutions.' Risk of inability to retain and hire key personnel is mentioned.
• Suppliers: Potential impact from optimizing manufacturing and supply chain, including procurement efficiencies, which could lead to changes in supplier relationships.
• Creditors: Waters will assume $4 billion of debt, but expects rapid deleveraging to below two times net leverage within 18 months, suggesting a healthy balance sheet post-transaction.

Next Steps

• Waters intends to file a registration statement on Form S-4, which will include a preliminary and definitive proxy statement/prospectus.
• SpinCo intends to file a registration statement on Form 10, which will serve as an information statement/prospectus.
• The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to required regulatory approvals, Waters shareholder approval, and other customary closing conditions.
• Waters will hold its second quarter financial results earnings call on August 4th.
• Waters and BD teams will work towards integrating the businesses and deploying Waters' operational playbook.
• The combined management team will be led by Udit Batra (CEO) and Amol Chaubal (CFO).

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, Reverse Morris Trust, M&A, acquisition, life science tools, flow cytometry, microbiology, mass spectrometry, liquid chromatography, analytical instruments, diagnostics, laboratory automation, biopharma, pharma, healthcare, R&D, financial performance, synergies, corporate governance, SEC filing